Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710032 | 0.92 | GRIK1 (0.36) | GRIK1MAPTLMNAABL1GRM5 | |
| SCHEMBL6710035 | 0.92 | GRIK1 (0.36) | GRIK1MAPTLMNAABL1GRM5 | |
| SCHEMBL6708862 | 0.92 | GRIK1 (0.36) | NR2E1GRIK1MAPTLMNAABL1 | |
| SCHEMBL6712474 | 0.90 | NR2E1 (0.34) | NR2E1MAPTLMNAABL1SMN1; SMN2 | |
| SCHEMBL6710021 | 0.87 | GRIK1 (0.39) | GRIK1MAPTLMNAABL1MEN1 | |
| SCHEMBL6709918 | 0.86 | GRIK1 (0.38) | GRIK1MAPTLMNAGRM5BACE1 | |
| SCHEMBL6713995 | 0.86 | NR2E1 (0.36) | NR2E1MAPTLMNAGRM4BACE1 | |
| SCHEMBL6712425 | 0.85 | TP53 (0.38) | GRIK1MAPTLMNAGRM5RAB9A | |
| SCHEMBL6709898 | 0.85 | GRIK1 (0.36) | GRIK1MAPTLMNAABL1GRM5 | |
| SCHEMBL6708956 | 0.85 | LRRK2 (0.38) | GRIK1MAPTLMNABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | NR2E1 2386/4885GRIK1 3885/4885MAPT 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.